Search Results

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial
by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 March 2014, Vol.32(8), pp.752-9

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
by Ornstein, Moshe C

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 June 2017, Vol.35(16), pp.1764-1769

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 May 2010, Vol.28(13), pp.2137-43

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
by Courtney, Kevin D

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, March 20, 2018, Vol.36(9), pp.867-874

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Re...
by Powles, Thomas

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, May 10, 2016, Vol.34(14), pp.1660-1668

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
by Motzer, Robert J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, December 10, 2017, Vol.35(35), pp.3916-3923

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
by Hammers, Hans J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 December 2017, Vol.35(34), pp.3851-3858

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 September 2009, Vol.27(27), pp.4462-8

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
by Choueiri, Toni K

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, January 1, 2008, Vol.26(1), pp.127-131

10.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 August 2008, Vol.26(22), pp.3743-8

11.

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
by Golshayan, Ali Reza

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, January 10, 2009, Vol.27(2), pp.235-241

12.

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer
by Rini, Brian I.

Journal of Clinical Oncology, 06/12/2000, Vol.18(12), pp.2419-2426

13.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell ca...
by Motzer, Robert J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, January 1, 2006, Vol.24(1), pp.16-24

Recommended databases

Find more Articles matching your search terms in these recommended databases.

All Libraries

Choose Your Library

Filter electronic articles 13 Hits

Remove Filters

Limit To: Peer reviewed (13)

Author: Rini, Brian I. (13); Rini, B.I. (13); Rini, Bi (10); more ...

Stadler, Walter M (4)

Bukowski, Ronald M (3)

Choueiri, Toni K (3)

Elson, Paul (3)

Escudier, Bernard (3)

Motzer, Robert J (3)

George, Daniel J (2)

Deprimo, Samuel E (2)

Wood, Laura S (2)

Wilding, George (2)

Zhou, Ming (2)

Figlin, Robert A (2)

Michaelson, M Dror (2)

Kim, Sindy T (2)

Ravaud, Alain (2)

Rosenberg, Jonathan E (2)

less ...

Journal Title: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology; Journal Of Clinical Oncology (13)

Subjects: Kidney Neoplasms (13); Carcinoma, Renal Cell (13); Aged (12); more ...

Aged, 80 And Over (9)

Humans (9)

Female (8)

Middle Aged (7)

Disease-Free Survival (6)

Pharmacy, Therapeutics, & Ph... (6)

Medicine (6)

Male (6)

Antineoplastic Combined Chemothe... (6)

Pyrroles (5)

Indoles (5)

Antineoplastic Agents (5)

Adult–Administration & Dosage (5)

Antibodies, Monoclonal (4)

Bevacizumab (4)

Adult–Therapeutic Use (4)

Angiogenesis Inhibitors (2)

less ...

Year of Publication: 2010-2019 (7); 2000-2009 (6)

Quelle: SciTech Premium Collection (13); Biological Science Database (13); Natural Science Collection (13); more ...

Health Research Premium Collecti... (13)

MEDLINE/PubMed (NLM) (13)

MEDLINE (ProQuest) (13)

Health Research Premium Collection (13)

Biological Science Index (ProQuest) (12)

Agricultural & Environmental... (8)

ProQuest Environmental Science C... (8)

Environmental Science Index (Pro... (7)

Environmental Science Collection... (7)

less ...

Suche

Filtern

Bibliotheken

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial
by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 March 2014, Vol.32(8), pp.752-9

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
by Ornstein, Moshe C

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 June 2017, Vol.35(16), pp.1764-1769

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 May 2010, Vol.28(13), pp.2137-43

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
by Courtney, Kevin D

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, March 20, 2018, Vol.36(9), pp.867-874

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Re...
by Powles, Thomas

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, May 10, 2016, Vol.34(14), pp.1660-1668

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
by Motzer, Robert J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, December 10, 2017, Vol.35(35), pp.3916-3923

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
by Hammers, Hans J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 December 2017, Vol.35(34), pp.3851-3858

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 September 2009, Vol.27(27), pp.4462-8

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
by Choueiri, Toni K

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, January 1, 2008, Vol.26(1), pp.127-131

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 August 2008, Vol.26(22), pp.3743-8

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
by Golshayan, Ali Reza

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, January 10, 2009, Vol.27(2), pp.235-241

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer
by Rini, Brian I.

Journal of Clinical Oncology, 06/12/2000, Vol.18(12), pp.2419-2426

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell ca...
by Motzer, Robert J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, January 1, 2006, Vol.24(1), pp.16-24

Recommended databases

All Libraries

Filter electronic articles 13 Hits

Suche

Filtern

Bibliotheken

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 March 2014, Vol.32(8), pp.752-9

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma by Ornstein, Moshe C

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 June 2017, Vol.35(16), pp.1764-1769

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 May 2010, Vol.28(13), pp.2137-43

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. by Courtney, Kevin D

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, March 20, 2018, Vol.36(9), pp.867-874

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Re... by Powles, Thomas

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, May 10, 2016, Vol.34(14), pp.1660-1668

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. by Motzer, Robert J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, December 10, 2017, Vol.35(35), pp.3916-3923

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study by Hammers, Hans J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 December 2017, Vol.35(34), pp.3851-3858

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 September 2009, Vol.27(27), pp.4462-8

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. by Choueiri, Toni K

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, January 1, 2008, Vol.26(1), pp.127-131

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma by Rini, Brian I

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 August 2008, Vol.26(22), pp.3743-8

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. by Golshayan, Ali Reza

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, January 10, 2009, Vol.27(2), pp.235-241

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer by Rini, Brian I.

Journal of Clinical Oncology, 06/12/2000, Vol.18(12), pp.2419-2426

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell ca... by Motzer, Robert J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, January 1, 2006, Vol.24(1), pp.16-24

Recommended databases

All Libraries

Filter electronic articles 13 Hits

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial
by Rini, Brian I

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
by Ornstein, Moshe C

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
by Rini, Brian I

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
by Courtney, Kevin D

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Re...
by Powles, Thomas

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
by Motzer, Robert J

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
by Hammers, Hans J

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
by Rini, Brian I

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
by Choueiri, Toni K

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
by Rini, Brian I

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
by Golshayan, Ali Reza

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer
by Rini, Brian I.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell ca...
by Motzer, Robert J